Arlocabtagene Autoleucel
Arlocabtagene Autoleucel, a GPRC5D-Targeted CAR T-cell Therapy, in Heavily Pretreated Multiple Myeloma: Updated Phase I Study Results

Released: December 12, 2024

Expiration: December 11, 2025

Activity

Progress
1
Course Completed